831 related articles for article (PubMed ID: 32562910)
21. Neuromyelitis optica spectrum disorders with a benign course. Analysis of 544 patients.
Lana-Peixoto MA; Talim NC; Callegaro D; Marques VD; Damasceno A; Becker J; Gonçalves MVM; Sato H;
Mult Scler Relat Disord; 2023 Jul; 75():104730. PubMed ID: 37156036
[TBL] [Abstract][Full Text] [Related]
22. Frequency of Aquaporin-4 Immunoglobulin G in Longitudinally Extensive Transverse Myelitis With Antiphospholipid Antibodies.
Guerra H; Pittock SJ; Moder KG; Fryer JP; Gadoth A; Flanagan EP
Mayo Clin Proc; 2018 Sep; 93(9):1299-1304. PubMed ID: 29655487
[TBL] [Abstract][Full Text] [Related]
23. Anti-MOG associated disorder-Clinical and radiological characteristics compared to AQP4-IgG+ NMOSD-A single-center experience.
Rempe T; Tarhan B; Rodriguez E; Viswanathan VT; Gyang TV; Carlson A; Tuna IS; Rees J
Mult Scler Relat Disord; 2021 Feb; 48():102718. PubMed ID: 33388560
[TBL] [Abstract][Full Text] [Related]
24. Clinical and demographic characteristics of patients with NMOSD: a longitudinal retrospective analysis of a Slovak cohort of 63 patients.
Szilasiová J; Gazda J; Mikula P; Cvengrošová A; Fedičová M; Hančinová V; Kantorová E; Karlík M; Kováčová S
Neurol Sci; 2024 Feb; 45(2):693-698. PubMed ID: 37698786
[TBL] [Abstract][Full Text] [Related]
25. Aquaporin-4-IgG positive neuromyelitis optica spectrum disorder in a paraneoplastic context.
Hyun JW; Park NY; Kim MJ; Kim H; Kim KH; Kim SH; Kim HJ
J Neurol Sci; 2023 Nov; 454():120825. PubMed ID: 37813018
[TBL] [Abstract][Full Text] [Related]
26. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin.
Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Trebst C; Ringelstein M; Aktas O; Winkelmann A; Buttmann M; Schwarz A; Zimmermann H; Brandt AU; Franciotta D; Capobianco M; Kuchling J; Haas J; Korporal-Kuhnke M; Lillevang ST; Fechner K; Schanda K; Paul F; Wildemann B; Reindl M;
J Neuroinflammation; 2016 Sep; 13(1):279. PubMed ID: 27788675
[TBL] [Abstract][Full Text] [Related]
27. Short transverse myelitis in Chinese patients with neuromyelitis optica spectrum disorders.
Hu H; You X; Ye J
Mult Scler Relat Disord; 2018 Apr; 21():78-83. PubMed ID: 29499441
[TBL] [Abstract][Full Text] [Related]
28. Neuromyelitis optica spectrum disorder: do patients positive and negative for anti-aquaporin-4 antibodies present distinct entities? A Colombian perspective.
Ortiz Salas PA; Gaviria Carrillo M; Cortés Bernal GA; Moreno Medina K; Roa LF; Rodríguez Quintana JH
Neurologia (Engl Ed); 2023 Sep; 38(7):504-510. PubMed ID: 35637138
[TBL] [Abstract][Full Text] [Related]
29. A Study of Neuromyelitis Optica Spectrum Disorders (NMOSD): Disease Pattern Based on Antibody Status.
Joshi PB; Shah SD; Patel MA; Shah SV; Darji SH; Mirche KC
Neurol India; 2022; 70(3):1131-1136. PubMed ID: 35864650
[TBL] [Abstract][Full Text] [Related]
30. Asymptomatic MRI lesions in pediatric-onset AQP4-IgG positive NMOSD.
Paolilo RB; Rimkus CM; da Paz JA; Apostolos-Pereira SL; Callegaro D; Sato DK
Mult Scler Relat Disord; 2022 Dec; 68():104215. PubMed ID: 36257150
[TBL] [Abstract][Full Text] [Related]
31. Neuromyelitis optica spectrum disorder in Western Mexico.
Mireles-Ramírez MA; Cortes-Enríquez F; Valdivia-Tangarife ER; Sanchez-Rosales NA; Hernandez-Preciado MR; Gonzalez-Rodriguez CH; García-Rivera JJ; Macias-Islas MA
Mult Scler Relat Disord; 2022 May; 61():103733. PubMed ID: 35339743
[TBL] [Abstract][Full Text] [Related]
32. Radiological characteristics of neuromyelitis optica spectrum disorder in Kuwait.
Ismail II; Ahmed SF; Al-Hashel JY; Abdelnabi EA; Alroughani R
Clin Neurol Neurosurg; 2020 Sep; 196():106047. PubMed ID: 32604036
[TBL] [Abstract][Full Text] [Related]
33. Status of the neuromyelitis optica spectrum disorder in Latin America.
Rivera VM; Hamuy F; Rivas V; Gracia F; Rojas JI; Bichuetti DB; Villa AM; Marques VD; Soto A; Bertado B; Frenk IT; Galleguillos L; Quiñones J; Ramirez DA; Caparó-Zamalloa C; Ciampi E; Lana-Peixoto MA; Rodríguez E; Zarco L; Sinay V; Armas E; Becker J; Benzadón A; Lopez E; Carnero Contentti E; Correa-Diaz EP; Diaz A; Fleitas CV; Playas G; Molina O; Rojas E; Sato D; Soto I; Céspedes JV; Correale J; Barboza A; Monterrey P; Candelario A; Tavolini DR; Parajeles A; Pujol BS; Diaz de la Fe A; Alonso R; Bolaña C; Guzman MK; Carrá A; Gamarra OG; Raggio JV; Rodriguez LC; Ramirez NE; Ordoñez L; Skromne E; Portillo LL; Canabal AP; Weiser R; Sirias V; Calderón RF; Cornejo EA; Hernández M; Quiroz JCD; Garcia LA; Cedeño CO; Martínez J; Abad-Herrera P
Mult Scler Relat Disord; 2021 Aug; 53():103083. PubMed ID: 34171682
[TBL] [Abstract][Full Text] [Related]
34. Clinical characteristics of 153 Brazilian patients with neuromyelitis optica spectrum disorder (NMOSD).
Fragoso YD; Sousa NAC; Alves-Leon SV; Dias RM; Pimentel MLV; Gomes S; Goncalves MVM; Stella CV; Tauil CB; Anacleto A; Spessotto CV; Correa EC; Eboni ACB; Damasceno A; Damasceno B; Farinhas JGD; Mota RSS; Nogueira EGA; Pereira VCSR; Scorcine C; Bacon T; Kister I
Mult Scler Relat Disord; 2019 Jan; 27():392-396. PubMed ID: 30504040
[TBL] [Abstract][Full Text] [Related]
35. Central nervous system inflammatory demyelinating disorders among Hong Kong Chinese.
Chan KH; Lee R; Lee JC; Tse AC; Pang SY; Lau GK; Teo KC; Ho PW
J Neuroimmunol; 2013 Sep; 262(1-2):100-5. PubMed ID: 23838529
[TBL] [Abstract][Full Text] [Related]
36. Clinical and radiological characteristics of neuromyelitis optica spectrum disorder in the North Egyptian Nile Delta.
Salama S; Marouf H; Ihab Reda M; Mansour AR; ELKholy O; Levy M
J Neuroimmunol; 2018 Nov; 324():22-25. PubMed ID: 30199734
[TBL] [Abstract][Full Text] [Related]
37. The clinical value of complement proteins in differentiating AQP4-IgG-positive from MOG-IgG-positive neuromyelitis optica spectrum disorders.
Qin C; Chen B; Tao R; Chen M; Ma X; Shang K; Wu LJ; Wang W; Bu BT; Tian DS
Mult Scler Relat Disord; 2019 Oct; 35():1-4. PubMed ID: 31276911
[TBL] [Abstract][Full Text] [Related]
38. The relationship between aquaporin-4 antibody status and visual tract integrity in neuromyelitis optica spectrum disorders: A visual evoked potential study.
Barć K; Gospodarczyk-Szot K; Nojszewska M; Podlecka-Piętowska A; Zakrzewska-Pniewska B
Mult Scler Relat Disord; 2020 Sep; 44():102265. PubMed ID: 32575026
[TBL] [Abstract][Full Text] [Related]
39. Clinical profile of patients with paraneoplastic neuromyelitis optica spectrum disorder and aquaporin-4 antibodies.
Sepúlveda M; Sola-Valls N; Escudero D; Rojc B; Barón M; Hernández-Echebarría L; Gómez B; Dalmau J; Saiz A; Graus F
Mult Scler; 2018 Nov; 24(13):1753-1759. PubMed ID: 28920766
[TBL] [Abstract][Full Text] [Related]
40. The risk factors of neuropathic pain in neuromyelitis optica spectrum disorder: a retrospective case-cohort study.
Li X; Xu H; Zheng Z; Ouyang H; Chen G; Lou Z; Chen H; Zhang J; Zhan Y; Mao H; Zhang C; Zhao M; Zhao Y
BMC Neurol; 2022 Aug; 22(1):304. PubMed ID: 35986246
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
